In a feature about innovative companies in Gent, Belgium, Kanaal Z – Canal Z City Reports reached out to our CEO Liesbeth Ceelen to learn more about what BioLizard is up to.
This video is only available in Dutch, however you can take a look at our company video to find out more about BioLizard in English.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
